Results 201 to 210 of about 187,331 (234)

The efficacy and safety of acupuncture compared to Western medicine in patients with nonalcoholic fatty liver disease: A systematic review and meta‐analysis

Precision Medical Sciences, EarlyView.
This study conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) to investigate whether acupuncture treatment is more beneficial than Western medicine treatment for patients with nonalcoholic fatty liver disease. The results showed that acupuncture was significantly superior to Western medicine in terms of clinical ...
Bin Yu, Yuxin Zhu, Yue Tong, Haomeng Zhang, Xiuli Lu, Hui He, Shuang Liang, Fuyu Xue, Haipeng Huang   +8 more
wiley   +1 more source

Correction to “The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis”

Portal Hypertension &Cirrhosis, EarlyView.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The clinical utility of apoB versus LDL-C/non-HDL-C

Clinica Chimica Acta, 2020
The ESC/EAS Guidelines and the EAS/EFLM consensus reports state that apoB is a more accurate marker of cardiovascular risk than LDL-C or non-HDL-C and that apoB can be measured accurately and precisely than LDL-C or non-HDL-C. Nevertheless, EAS/EFLM called for a randomized clinical trial and a cost-effective analysis before widespread implementation of
Ciarán N Kohli-Lynch, George Thanassoulis, Andrew E Moran   +2 more
exaly   +3 more sources

ApoB versus non-HDL-C: What to do when they disagree

Current Atherosclerosis Reports, 2009
The high correlation between apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (non-HDL-C) is the chief argument employed against introducing apoB into clinical practice. However, high correlation does mean that non-HDL-C and apoB will often yield similar clinical information. Nevertheless, the critical issue is not how often the two
Allan, Sniderman, Ken, Williams, Christa, Cobbaert   +2 more
openaire   +2 more sources

Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C

Heart Lung and Circulation, 2016
Recent guidelines recommended both low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) are the primary target of lipid modulating therapy. However, which lipid measure is most closely related to the severity of coronary atherosclerosis has not yet been assessed.We studied 1757 consecutive subjects ...
Na-Qiong Wu, Cheng-Gang Zhu, Yuan-Lin Guo   +2 more
exaly   +3 more sources

Non-HDL C equals apolipoprotein B: except when it does not!

Current Opinion in Lipidology, 2010
Whether national guidelines should incorporate apolipoprotein B (apoB) into clinical practice is one of the most important and contentious decisions they must face. Canada has chosen to do so. What Europe and America decide remains to be seen.Obviously, the results of the major epidemiological studies and clinical trials should be major drivers of ...
Sniderman, A., Williams, K., Graaf, J. de   +2 more
openaire   +3 more sources

ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk

Journal of Clinical Lipidology
Conventional statistical approaches are not designed to compare highly correlated variables such as low-density lipoprotein cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB). Discordance analysis was designed to overcome this limitation by creating groups in which the predictions of 2 markers differ ...
Daniel Sehayek, Justine Cole, Elias Björnson, John T. Wilkins, Martin B. Mortensen, Line Dufresne, Karol M. Pencina, Michael J. Pencina, George Thanassoulis, Allan D. Sniderman   +9 more
openaire   +3 more sources

In diabetes, some statins reduce non–HDL-C better than others vs. placebo

Annals of Internal Medicine, 2022
Hodkinson A, Tsimpida D, Kontopantelis E, et al. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022;376:e067731. 35331984.
openaire   +2 more sources

Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome

Wiener klinische Wochenschrift, 2016
Changes in high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels have been linked to residual cardiovascular risk, whereas non-HDL-C levels have been shown to be more predictive of cardiovascular risk than are low-density lipoprotein cholesterol (LDL-C) levels. We aimed to investigate the impact of HDL-C, TG, and non-HDL-C levels on
Péter, Koncsos, Péter, Fülöp, Imre, Juhász, Klára, Bíró, László, Márk, Gábor, Simonyi, György, Paragh   +6 more
openaire   +2 more sources

An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB

Journal of Clinical Lipidology, 2016
The National Lipid Association (NLA) selected non-HDL-C as its prime index of the cardiovascular risk associated with the apoB lipoproteins. ApoB was recommended only as an optional secondary target after low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (HDL-C) targets were achieved.The aims of this analysis were
Allan D, Sniderman, Peter P, Toth, George, Thanassoulis, Curt D, Furberg   +3 more
openaire   +2 more sources